SUMMARYFour monovalent experimental vaccines (VI, V2, V3 and V7) containing an Argentinean serovar B strain (H8) of Haemophilus paragallinarum and three different commercial vaccines, either bivalent (V4 and V5) containing serovars A and C, or trivalent (V6) containing serovars A, B and C were administered by subcutaneous or intramuscular routes as a single or double dose (at 3-week intervals) to chickens of between 6 and 10 weeks. Three to 7 weeks after the last vaccination, vaccinated and non-vaccinated chickens were challenged by intrasinus inoculation with Argentinean serovar B strains of H. paragallinarum. When the vaccinated chickens were exposed to a severe challenge with the vaccinal strain (H8) some experimental vaccines protected, whereas all commercial vaccines failed to protect. The experimental vaccines manufactured in broth (V2, V3 and V7) protected more effectively than the vaccine produced in chicken embryos (VI). Failure of the commercial trivalent vaccine V6 to protect may be related to the method of manufacture. Vaccine V7 protected against challenge from either the vaccinal strain (H8) or three Argentinean serovar B strains (H6, Hll and HI2). These results confirm the necessity of including serovar B regional strains in the formulation of local vaccines.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.